ラスクフロキサシン
English Journal
- Pharmacokinetic study of lascufloxacin in non-elderly healthy men and elderly men.
- Totsuka K, Sesoko S, Fukase H, Ikushima I, Odajima M, Niwayama Y.
- Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2020 Mar;26(3)231-239.
- We conducted this phase I clinical study to examine the pharmacokinetic profiles and safety of lascufloxacin (LSFX), a novel quinolone antibacterial agent, in non-elderly Japanese healthy men and the effects of aging on LSFX pharmacokinetics in elderly Japanese healthy men. 1. After single-dose oral
- PMID 31882385
- Ohya K, Takano J, Manita S.
- Antimicrobial agents and chemotherapy. 2019 04;63(4).
- The present study aimed to clarify the mechanism underlying the high distribution of lascufloxacin in epithelial lining fluid (ELF). Involvement of transporters was examined by transcellular transport across Calu-3 and transporter-overexpressing cells; the binding of lascufloxacin to ELF components
- PMID 30718243
- In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group.
- Yamagishi Y, Matsukawa Y, Suematsu H, Mikamo H.
- Anaerobe. 2018 Dec;54()61-64.
- The in vitro activities of lascufloxacin were evaluated by comparison with seven reference compounds using 412 clinical isolates of anaerobes and Streptococcus anginosus group. Lascufloxacin showed potent and broad antibacterial activities greater than those of existing quinolones against the clini
- PMID 30114441
Japanese Journal
- 新薬紹介委員会
- ファルマシア 56(3), 241-243, 2020
- 本稿では既に「承認薬の一覧」に掲載された新有効成分含有医薬品など新規性の高い医薬品について，各販売会社から提供していただいた情報を一般名，市販製剤名，販売会社名，有効成分または本質および化学構造，効能・効果を一覧として掲載しています．<br>今回は，55巻12号「承認薬の一覧」に掲載した当該医薬品について，表解しています．<br>なお，「新薬のプロフィル」欄においても詳解し …
- NAID 130007804252
- In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions
- Murata Mika,Kosai Kosuke,Yamauchi Shunsuke,Sasaki Daisuke,Kaku Norihito,Uno Naoki,Morinaga Yoshitomo,Hasegawa Hiroo,Miyazaki Taiga,Izumikawa Koichi,Mukae Hiroshi,Yanagihara Katsunori
- Antimicrobial Agents and Chemotherapy 62(4), 01971-17, 2018-04
- … Lascufloxacin showed potent activity against Streptococcus pneumoniae with a GyrA or ParC mutation (first-step mutant). … The frequency of selecting resistant strains tended to be lower for lascufloxacin than for levofloxacin and garenoxacin after drug exposure in first-step mutants but was similar in the comparison between lascufloxacin and moxifloxacin. …
- NAID 120006491666
Related Links
- Lascufloxacin hydrochloride (JAN) 商品名 ラスビック (杏林製薬) 組成式 C21H24F3N3O4. HCl 質量 475.1486 分子量 475.8891 構造式 クラス 抗菌薬 DG01550 キノロン系抗生物質 DG01549 フルオロキノロン系抗生物質 コード 6241 ...
- Lascufloxacin | C21H24F3N3O4 | CID 71528768 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities ...
- Lascufloxacin、visionary and conceptual quinoloneから命名 1錠薬価 361.40円 361.40円 日本で一番処方されているニューキノロン系抗菌薬クラビットは第一三共が創製した薬だがラスビックも日本の杏林が創製した。 世界初のニュー ...
★リンクテーブル★
[★]
- 英
- lascufloxacin
- 商
- ラスビック
- 関
- 抗菌薬